drugset / Trial / NCT02269475
A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
RandomizedParallel-groupDouble-blindPrevention
Summary
The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 to 18 years of age that would support approval of MEDI3250 in Japan.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-04
- Completion
- 2015-04
Outcome
Missed primary endpoint
registry Vaccine efficacy (%) 100.0 (95% CI -1875.3 to 100.0) NCT02269475 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI3250 | Vaccine | 0.2 ml | Intranasal |
Indications
No indication recorded.